

Jing Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3433393/publications.pdf>

Version: 2024-02-01

31
papers

1,243
citations

516561

16
h-index

477173

29
g-index

33
all docs

33
docs citations

33
times ranked

1265
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. <i>Thoracic Cancer</i> , 2022, 13, 1631-1641.	0.8	8
2	Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3086-3086.	0.8	0
3	Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: A prospective, open-label, phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4041-4041.	0.8	2
4	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 562-568.	1.4	7
5	Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. <i>Cancer Medicine</i> , 2021, 10, 1681-1689.	1.3	39
6	SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. <i>Thoracic Cancer</i> , 2021, 12, 1373-1381.	0.8	15
7	Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. , 2021, 9, e002224.		41
8	Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16097-e16097.	0.8	0
9	Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 403-414.	1.1	3
10	HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. , 2020, 8, e001279.		11
11	Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. <i>Cancer Communications</i> , 2020, 40, 711-720.	3.7	68
12	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCOR): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 832-842.	5.1	350
13	Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3139-3139.	0.8	1
14	Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16036-e16036.	0.8	2
15	Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. <i>Cancer Biology and Medicine</i> , 2019, 16, 173.	1.4	47
16	Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2019, 10, 1395-1401.	0.8	33
17	Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-label phase 3 trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	17
18	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	2.0	55

#	ARTICLE	IF	CITATIONS
19	Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 95-95.	0.8	12
20	Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 910-917.	0.7	7
21	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	3.2	146
22	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. <i>British Journal of Cancer</i> , 2018, 119, 538-545.	2.9	111
23	Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. <i>BMC Cancer</i> , 2018, 18, 547.	1.1	15
24	Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 149-155.	0.7	20
25	Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 24744-24751.	0.8	25
26	Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 910-917.	0.5	51
27	Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , 2016, 7, 246-250.	0.8	13
28	Adjuvant chemotherapy after esophagectomy: Is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?. <i>Journal of Surgical Oncology</i> , 2014, 110, 864-868.	0.8	49
29	A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. <i>Medical Oncology</i> , 2013, 30, 343.	1.2	50
30	Primary small cell carcinoma of the stomach: An experience of two decades (1990-2011) in a Chinese cancer institute. <i>Journal of Surgical Oncology</i> , 2012, 106, 994-998.	0.8	18
31	Sequential development of diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. <i>Diagnostic Cytopathology</i> , 2012, 40, 346-351.	0.5	21